Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2012

View Archived Issues

ISU Abxis reports on phase II program for Fabry's disease

PDS Biotechnology and Merck KGaA enter new license agreement

Data reported from five clinical studies of panobinostat

Capricor clear to advance clinical testing of stem cell therapy for myocardial regeneration

Novel potential Gaucher's disease drugs designed in U.S.

Investigators in China develop new candidate cognition-enhancing drugs

GSK patents novel inhibitors of LDL-PLA2

Research in Shanghai yields new c-Met inhibitors

Alchemia demerges oncology business

Rhizen Pharmaceuticals presents novel candidate steatohepatitis/diabetes drugs

Japanese approval sought for subcutaneous arthritis drug

Ligand Pharmaceuticals divulges new results on LGD-6972

Zalicus kicks off multiple-ascending-dose Z-944 study

OncoVista obtains IND clearance for solid tumor therapy

Galenea enters neuroscience collaboration

FDA accepts resubmitted raxibacumab BLA

Shionogi-ViiV Healthcare discloses initial data from SINGLE trial

CYT-017 obtains orphan drug status

Ohr Pharmaceutical reports encouraging preclinical data on squalamine eye drop

Inotuzumab ozogamicin shows promise in NHL and ALL

BioInvent announces topline results from GLACIER trial

FDA grants orphan drug status to cell therapy for Hurler's syndrome

Cangene discontinues program

TD-1211 trial meets primary endpoint

Viralytics initiates extension of CALM trial

Nymox provides update on phase III NX-1207 study

Research in Taiwan reveals new potential target for ovarian cancer therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...